Explore the Use of Cortical Oxygenation Measures in Nutrition Research

NCT ID: NCT07191665

Last Updated: 2025-09-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

37 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-11-20

Study Completion Date

2025-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The current project aims to explore the use of cortical oxygenation measures obtained with functional Near Infrared Spectroscopy (fNIRS) in acute nutrition interventions with outcomes on cognition.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The project aims to test a previously developed fNIRS-based protocol for evaluating the acute effects of dietary components on cognitive function in a population of healthy young adults. The testing will involve detecting patterns in fNIRS-based cortical tissue oxygenation level and cognitive performance that are expected due to the bioactive mechanisms of the studied components.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy adults

Healthy males and females aged between 25 and 35 years old.

Acute nutrition intervention

Intervention Type OTHER

The products (investigational and placebo) consists of three capsules that should be taken with water at two separate visits, with a wash-out period in between. The placebo product will comprise of microcrystalline cellulose (bulk). The investigational products will contain either caffeine and microcrystalline cellulose or caffeine, L-Arginine, and microcrystalline cellulose.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acute nutrition intervention

The products (investigational and placebo) consists of three capsules that should be taken with water at two separate visits, with a wash-out period in between. The placebo product will comprise of microcrystalline cellulose (bulk). The investigational products will contain either caffeine and microcrystalline cellulose or caffeine, L-Arginine, and microcrystalline cellulose.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and Females 25-35 years old
* BMI between 18.5 kg/m2 and 29.9 kg/m2
* Conditions for study procedure compliance:

* Willing and able to sign an informed consent form
* Fluent in English (self-reported C1 or C2 English level)
* Have reliable cortical oxygenation signal for subsequent analysis (based on the real-time computation of a parameter reflecting the quality of the signal, which may be influenced by variations in hair thickness)
* Dominant right-handed
* Have normal or corrected-to-normal vision
* Willing and able to comply with the protocol requirements

Exclusion Criteria

* Conditions that may affect cortical oxygenation:

* Have a past or current neural, cerebrovascular, cardiovascular, or respiratory disease (based on anamnesis)
* Have a past or current kidney disease or condition (based on anamnesis)
* Measured hypo- or hyper-tension (verified by evaluating Blood Pressure, BP, measure against medical norms at screening)
* Self-reported, suspected or diagnosed migraine (based on anamnesis)
* Have a mild or clinical form of insomnia (verified by thresholding rated insomnia severity index, ISI, at or above 8) or being a night shift worker (based on anamnesis)
* Regular smoker, regularly is being defined as more than 2 cigarettes per week
* Participating in vigorous physical activity defined as requiring more than 6 metabolic equivalents (e.g., hiking, jogging at 10 km/h or more, carrying of heavy loads, bicycling fast at 23 km/h or more, basketball, soccer, and tennis single), greater than 4 times 45 minutes per week
* Conditions that may affect cognition or mental fatigue:

* Have a current psychiatric disorder or have a self-reported, suspected or diagnosed anxiety or depression (based on anamnesis)
* Taking illicit drugs for e.g., cannabis, heroin, and cocaine
* Have an average alcohol consumption defined as greater than 2 standard drinks per day over a week for males, and greater than 1 standard drink per day over a week for females. One standard drink contains 10-12 g of ethanol. Examples of standard drinks are one beer can (300 ml), one glass of wine (100 ml) or one glass of schnaps (30 ml).
* Pregnant (verified by a pregnancy test in urine dipstick format provided by the study's site) or seeking to become pregnant or breast feeding (based on anamnesis)
* Conditions that may interact with the IP mechanism:

* Have food allergies and intolerances (based on anamnesis)
* Have a high usual consumption of caffeine-based beverages and foods (verified by thresholding the daily consumption of caffeine as determined by the Caffeine Consumption Questionnaire, CCQ, at or above 600mg)
* Body mass below 60kg (associated with a dosing of more than 3mg caffeine per 1kg of body mass)
* Currently taking Sildenafil (based on anamnesis)
* Self-reported, suspected or diagnosed with acute inflammatory diseases e.g., herpes simplex virus, allergies, or asthma (based on anamnesis)
* Have a hierarchal or family relationship with any of the research team members.
* Currently participating in an interventional study.
Minimum Eligible Age

25 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ecole Polytechnique Fédérale de Lausanne

OTHER

Sponsor Role collaborator

Société des Produits Nestlé (SPN)

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pamela Pamela, Medical

Role: PRINCIPAL_INVESTIGATOR

Société des Produits Nestlé

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Innovation Lab

Lausanne, Canton of Vaud, Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2305NR

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Color and Pupil Function
NCT02636140 COMPLETED NA
Systematic Psychophysical
NCT06965478 RECRUITING NA